Stealth Biotech published recent clinical findings showing that some individuals diagnosed with relapsing-remitting multiple sclerosis (MS) can benefit from anti-CD20 B cell therapies, indicating a potentially pathogenic role for autoreactive B cells.

Signal category

Research & Knowledge

Quote

“Recent clinical findings have shown that some individuals diagnosed with relapsing-remitting multiple sclerosis (MS) can benefit from anti-CD20 B cell therapies, indicating a potentially pathogenic role for autoreactive B cells.”

— Dr. Andreas Herrmann, PhD|Stealth Biotech team